These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 19196540

  • 21. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
    Grégoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T.
    Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
    [Abstract] [Full Text] [Related]

  • 22. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM.
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [Abstract] [Full Text] [Related]

  • 23. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [Abstract] [Full Text] [Related]

  • 24. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
    [Abstract] [Full Text] [Related]

  • 25. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 26. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N, Morissette M, Grégoire L, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan 02; 56():27-38. PubMed ID: 25046277
    [Abstract] [Full Text] [Related]

  • 27. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.
    Neurobiol Aging; 2010 Jun 02; 31(6):926-36. PubMed ID: 18707801
    [Abstract] [Full Text] [Related]

  • 28. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H, Bartoszyk GD, Quartermain D, Lin Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar 02; 30(2):273-9. PubMed ID: 16229932
    [Abstract] [Full Text] [Related]

  • 29. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
    Samadi P, Grégoire L, Rassoulpour A, Guidetti P, Izzo E, Schwarcz R, Bédard PJ.
    Mov Disord; 2005 Jul 02; 20(7):792-802. PubMed ID: 15954116
    [Abstract] [Full Text] [Related]

  • 30. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.
    Neurosci Res; 2013 Dec 02; 77(4):242-6. PubMed ID: 24135129
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 02; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

  • 33. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 02; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 34. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.
    Neuropharmacology; 2014 Apr 02; 79():688-706. PubMed ID: 24456747
    [Abstract] [Full Text] [Related]

  • 35. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    Mov Disord; 1998 Sep 02; 13(5):798-802. PubMed ID: 9756148
    [Abstract] [Full Text] [Related]

  • 36. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 02; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 37. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb 02; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 38. AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
    Bourque M, Grégoire L, Patel W, Dickens D, Snodgrass R, Di Paolo T.
    Cells; 2022 Nov 08; 11(22):. PubMed ID: 36428960
    [Abstract] [Full Text] [Related]

  • 39. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P, Grégoire L, Rouillard C, Bédard PJ, Di Paolo T, Lévesque D.
    Ann Neurol; 2006 Feb 08; 59(2):282-8. PubMed ID: 16437566
    [Abstract] [Full Text] [Related]

  • 40. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.
    Mov Disord; 2019 May 08; 34(5):708-716. PubMed ID: 30575996
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.